AFP and hepatocellular carcinoma: Their network meta-analysis revealed that in patients with advanced HCC and elevated AFP levels (400 ng/mL or higher), there were no significant differences in PFS, OS, ORR, or DCR when comparing regorafenib, cabozantinib, or lamuximab.